Sumitomo Pharma Co., Ltd.
DNPUFOTCHealthcare● Active
$10.50
+$1.13(+12.06%)
Market Cap$4.7B
P/E Ratio—
52W High$19.2
52W Low$6.34
Sumitomo Pharma Co., Ltd. (DNPUF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DNPUF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $456.15B | $398.83B | $314.56B | $555.54B | $560.03B |
| Cost of Revenue | $197.64B | $153.44B | $126.58B | $178.92B | $157.13B |
| Gross Profit | $258.51B | $245.40B | $187.98B | $376.63B | $402.91B |
| Gross Margin %(computed) | 56.67% | 61.53% | 59.76% | 67.79% | 71.94% |
| Operating Expenses | |||||
| R&D Expenses | $44.27B | $49.90B | $112.64B | $131.86B | $94.90B |
| G&A Expenses | $0.00B | $135.39B | $429.54B | $279.36B | $179.56B |
| Total Operating Expenses | $207.85B | $230.47B | $542.84B | $453.60B | $342.67B |
| Operating Income | $50.66B | $14.93B | ($354.86B) | ($76.98B) | $60.23B |
| Operating Margin %(computed) | 11.11% | 3.74% | -112.81% | -13.86% | 10.76% |
| Interest Income | $3.22B | $2.31B | $36.02B | $32.22B | $25.78B |
| Interest Expense | $10.26B | $13.50B | $4.28B | $3.16B | $3.05B |
| Income Before Tax | $100.98B | $17.61B | ($323.11B) | ($47.92B) | $82.96B |
| Income Tax Expense | ($6.56B) | ($6.02B) | ($8.19B) | $48.79B | $42.36B |
| Net Income | $107.54B | $23.63B | ($314.97B) | ($74.51B) | $56.41B |
| Net Margin %(computed) | 23.58% | 5.93% | -100.13% | -13.41% | 10.07% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $270.03 | $59.49 | $-792.79 | $-187.55 | $141.99 |
| Wtd Avg Shares | 0.40B | 0.40B | 0.40B | 0.40B | 0.40B |
| EBITDA | $71.57B | $38.59B | ($317.37B) | ($3.50B) | $98.31B |
| EBITDA Margin %(computed) | 15.69% | 9.67% | -100.89% | -0.63% | 17.56% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · JPY · B
Explore more Sumitomo Pharma Co., Ltd. data
About Sumitomo Pharma Co., Ltd. (DNPUF) Income Statement
Sumitomo Pharma Co., Ltd. (DNPUF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2026, DNPUF reported revenue of $456.15B, gross profit of $258.51B (gross margin 56.67%), and net income of $107.54B — a net profit margin of 23.58%.
Frequently asked questions
DNPUF · 4 questionsSumitomo Pharma Co., Ltd. (DNPUF) reported revenue of $456.15B for 2026, up 14.4% year-over-year.
DNPUF revenueDNPUF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09